Welcome to our dedicated page for Kura Oncology SEC filings (Ticker: KURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Kura Oncology, Inc. Chief Medical Officer Mollie Leoni sold 84,929 shares of common stock in an open-market transaction on June 18, 2026 at a weighted average price of $9.8233 per share. The trades were executed in multiple lots at prices ranging from $9.56 to $9.98.
The shares sold had been acquired upon vesting of restricted stock units and performance restricted stock units between January 26, 2022 and January 26, 2026. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026. Following this transaction, Leoni directly holds 182,345 Kura Oncology shares.
Kura Oncology, Inc. director Diane L. Parks received an option grant for 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. According to the grant terms, it vests in full on the one-year anniversary of the grant date.
Kura Oncology director Michael Vasconcelles received a new stock option grant covering 35,000 shares of common stock. The option has an exercise price of $8.77 per share and was granted at no upfront cost. It vests in full on the one-year anniversary of the grant date and expires on June 3, 2036. Following this award, Vasconcelles holds options for 35,000 shares directly, reflecting a compensation-related grant rather than an open-market trade.
Kura Oncology, Inc. director Faheem Hasnain reported receiving an option grant to purchase 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. Following this grant, Hasnain holds options for 35,000 shares. The award vests in full on the one-year anniversary of the grant date, making it a standard equity compensation grant rather than an open-market purchase.
Kura Oncology director Helen Louise Collins received a new stock option grant that increases her potential equity stake in the company. She was awarded options to purchase 35,000 shares of common stock at an exercise price of $8.77 per share. The options vest in full on the one-year anniversary of the grant date and expire on June 3, 2036. Following this grant, she holds options covering 35,000 shares directly.
Kura Oncology director Carol Schafer received a grant of stock options, acquiring options to purchase 35,000 shares of common stock at an exercise price of $8.77 per share. These options vest in full on the one-year anniversary of the grant date and expire on June 3, 2036. Following this compensation-related award, Schafer holds 35,000 options directly, with no indication of open-market buying or selling in this filing.
Kura Oncology reported that director Mary T. Szela received an option grant to purchase 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. It vests in full on the one-year anniversary of the grant date, and following this award she holds 35,000 options directly.
Kura Oncology director Thomas Malley received a stock option grant covering 35,000 shares of common stock. The option has an exercise price of $8.77 per share and was reported as a grant or award, not an open-market purchase or sale.
The option vests in full on the one-year anniversary of the grant date and expires on June 3, 2036 if not exercised. Following this award, Malley’s reported derivative holdings in this option total 35,000 underlying shares, reflecting a compensation-related equity incentive rather than a discretionary trade.
Kura Oncology, Inc. reported results of its Annual Meeting of Stockholders and approval of expanded equity compensation plans. Stockholders approved amendments to the 2014 Equity Incentive Plan adding 6,500,000 shares and to the 2015 Employee Stock Purchase Plan adding 2,500,000 shares for future awards.
As of the April 6, 2026 record date, 88,762,704 shares of common stock were outstanding, and 69,778,580 shares were present or represented by proxy. Stockholders elected three Class III directors to terms ending at the 2029 annual meeting, ratified Ernst & Young LLP as auditor, approved executive compensation on an advisory basis, chose an annual say‑on‑pay vote, and confirmed both the amended equity plan and ESPP.